| Autor: |
Shusuke Yagi, Akihiro Kudo, Noritaka Machii, Toshio Ono, Yoshito Oshiro, Ryu Takahashi, Yoshinobu Taneda, Ken Nakachi |
| Jazyk: |
angličtina |
| Rok vydání: |
2023 |
| Předmět: |
|
| Zdroj: |
BMJ Open Diabetes Research & Care, Vol 11, Iss 2 (2023) |
| Druh dokumentu: |
article |
| ISSN: |
2052-4897 |
| DOI: |
10.1136/bmjdrc-2022-003302 |
| Popis: |
Introduction This study aimed to evaluate the impacts of dapagliflozin on 24-hour glucose variability and diabetes-related biochemical variables in Japanese patients with type 2 diabetes who had received basal insulin supported oral therapy (BOT).Research design and methods Changes in mean daily blood glucose level before and after 48–72 hours of add-on or no add-on of dapagliflozin (primary end point) and diabetes-related biochemical variables and major safety variables during the 12 weeks (secondary end point) were evaluated in the multicenter, randomized, two-arm, open-label, parallel-group comparison study.Results Among 36 participants, 18 were included in the no add-on group and 18 were included in the dapagliflozin add-on group. Age, gender, and body mass index were comparable between the groups. There were no changes in continuous glucose monitoring metrics in the no add-on group. In the dapagliflozin add-on group, mean glucose (183–156 mg/dL, p=0.001), maximum glucose (300–253, p |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
